SCHEDULE 13G/A: Adage Capital Management Discloses 7.6% Stake in Aclaris Therapeutics
Beneficial Ownership Report
Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, has reported a beneficial ownership of 7.6% in Aclaris Therapeutics, Inc. common stock.
Summary
- Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross collectively reported beneficial ownership of 8,201,344 shares of Aclaris Therapeutics, Inc. Common Stock.
- This ownership represents 7.60% of Aclaris Therapeutics' outstanding Common Stock.
- The percentage is calculated based on 107,918,821 shares of Common Stock outstanding as of January 31, 2025, as reported in the Company's Annual Report on Form 10-K.
- The reporting persons, including Adage Capital Management, L.P. (an investment manager), Robert Atchinson, and Phillip Gross, share both voting and dispositive power over these shares.
- The filing is an Amendment No. 1 to a Schedule 13G, indicating a change in previously reported beneficial ownership.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Aclaris Therapeutics, Inc.
Sentiment
Score: 6
Explanation: The disclosure of a significant stake by a reputable institutional investor like Adage Capital Management is generally viewed as a neutral to slightly positive signal, indicating institutional interest and liquidity in the stock, without implying any specific operational or financial performance.
Positives
- A significant institutional investor, Adage Capital Management, L.P., holds a substantial stake, which can be viewed as a vote of confidence in Aclaris Therapeutics, Inc.
Risks
- The filing explicitly states that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer, indicating a passive investment approach by the reporting persons.
Future Outlook
This document does not contain any forward-looking statements or guidance regarding the issuer's future performance or outlook.
Industry Context
The filing indicates a significant passive investment by a prominent institutional asset manager in a biotechnology company. Such filings are common in the biotech sector, where institutional investors often take positions in companies with promising pipelines or market potential, reflecting their investment strategies rather than direct operational involvement.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant ownership stakes, which can influence market perception and trading activity. The presence of a large institutional holder may offer some stability or signal confidence.
Key Dates
| Date | Description |
|---|---|
| 2025-01-31 | Date as of which 107,918,821 shares of Common Stock were reported outstanding in the Company's 10-K. |
| 2025-02-27 | Date Aclaris Therapeutics, Inc. filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. |
| 2025-03-31 | Date of event which requires the filing of this statement (beneficial ownership threshold met or changed). |
| 2025-05-12 | Date the Schedule 13G Amendment No. 1 was signed and filed. |
Keywords
Aclaris Therapeutics, Adage Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Pharmaceuticals, SEC Filing, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.